Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Icosavax (ICVX) News Today

Icosavax logo
Vaxcyte Inc Ordinary Shares 5VA
NervGen Pharma Corp Ordinary Shares NGEN
Icosavax, Inc. stock logo
Icosavax, Inc. (NASDAQ:ICVX) Shares Bought by Barclays PLC
Barclays PLC grew its holdings in Icosavax, Inc. (NASDAQ:ICVX - Free Report) by 3,589.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 202,182 shares of the company's stock after purchasing an additional 196,702 share
Icosavax: Tender Offer With Contingent Value Right
Icosavax, Inc. stock logo
Icosavax, Inc. (NASDAQ:ICVX) CEO Sells $229,350.00 in Stock
Icosavax, Inc. (NASDAQ:ICVX - Get Free Report) CEO Adam K. Simpson sold 15,000 shares of the company's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $15.29, for a total transaction of $229,350.00. Following the transaction, the chief executive officer now directly owns 358,657 shares of the company's stock, valued at approximately $5,483,865.53. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Icosavax CVR Seems Fairly Valued
Icosavax, Inc. stock logo
Adam K. Simpson Sells 15,000 Shares of Icosavax, Inc. (NASDAQ:ICVX) Stock
Icosavax, Inc. (NASDAQ:ICVX - Get Free Report) CEO Adam K. Simpson sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $15.67, for a total transaction of $235,050.00. Following the completion of the sale, the chief executive officer now directly owns 260,641 shares of the company's stock, valued at approximately $4,084,244.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Guggenheim Downgrades Icosavax (ICVX)
Icosavax, Inc. stock logo
Icosavax's (ICVX) "Neutral" Rating Reiterated at Guggenheim
Guggenheim reissued a "neutral" rating on shares of Icosavax in a research note on Tuesday.
Icosavax, Inc. stock logo
Insider Selling: Icosavax, Inc. (NASDAQ:ICVX) Insider Sells 11,884 Shares of Stock
Icosavax, Inc. (NASDAQ:ICVX - Get Free Report) insider Niranjan Kanesa-Thasan sold 11,884 shares of the business's stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $15.46, for a total value of $183,726.64. Following the completion of the transaction, the insider now owns 223,980 shares of the company's stock, valued at $3,462,730.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
ICVX Jul 2024 15.000 call
Icosavax, Inc. stock logo
Icosavax, Inc. (NASDAQ:ICVX) Short Interest Down 5.6% in November
Icosavax, Inc. (NASDAQ:ICVX - Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 1,680,000 shares, a decrease of 5.6% from the November 15th total of 1,780,000 shares. Approximately 5.2% of the company's shares are sold short. Based on an average daily volume of 317,300 shares, the short-interest ratio is presently 5.3 days.
Icosavax, Inc. stock logo
Cassia Cearley Sells 8,759 Shares of Icosavax, Inc. (NASDAQ:ICVX) Stock
Icosavax, Inc. (NASDAQ:ICVX - Get Free Report) insider Cassia Cearley sold 8,759 shares of the stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $16.01, for a total value of $140,231.59. Following the sale, the insider now owns 131,200 shares of the company's stock, valued at $2,100,512. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Icosavax, Inc. stock logo
Icosavax (NASDAQ:ICVX) Downgraded by William Blair
William Blair cut shares of Icosavax from an "outperform" rating to a "market perform" rating in a research note on Tuesday.
Icosavax just downgraded at Jefferies, here's why
Icosavax just downgraded at William Blair, here's why
Icosavax initiated with a Buy at Guggenheim
TD Cowen Keeps Their Buy Rating on Icosavax (ICVX)
Aura Biosciences GAAP EPS of -$0.48
Icosavax, Inc. stock logo
Tower Research Capital LLC TRC Acquires 20,910 Shares of Icosavax, Inc. (NASDAQ:ICVX)
Tower Research Capital LLC TRC increased its stake in shares of Icosavax, Inc. (NASDAQ:ICVX - Free Report) by 1,516.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,289 shares of the company's stock after acquiring a
Jefferies Reaffirms Their Buy Rating on Icosavax (ICVX)
Get Icosavax News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICVX and its competitors with MarketBeat's FREE daily newsletter.

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here << 

ICVX Media Mentions By Week

ICVX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ICVX
News Sentiment

0.00

0.59

Average
Medical
News Sentiment

ICVX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ICVX Articles
This Week

0

0

ICVX Articles
Average Week

Get Icosavax News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICVX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ICVX) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners